NCX-701. NicOx.
NicOx is developing NCX-701, a nitric oxide-releasing derivative of paracetamol (acetaminophen), for the potential treatment of inflammation and pain. The compound is currently undergoing phase III clinical trials.
University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9068, USA. girish.joshi@utsouthwestern.edu
Girish P
GP
Joshi
D000082:Acetaminophen / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D001682:Biological Availability; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004345:Drug Industry; D015507:Drugs, Investigational; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D015394:Molecular Structure; D009566:Nitrates / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015507:Drugs, Investigational; D009566:Nitrates; D000082:Acetaminophen; C478738:4-(nitroxy)butanoic acid 4-acetylaminophenyl ester